Pharmaceutical titan Eli Lilly has delivered a quarterly report that dramatically surpassed market forecasts, sending waves ...

The drug, which Lilly in-licensed four years ago and is designed to inhibit a protein known as P2X7, did not meet the company ...

The live event in Nashville, Tenn., featured 60-plus leaders, and also honored several companies with awards for supply chain excellence.

Major stock indexes declined Thursday as investors digested several big tech earnings reports and awaited more after the ...

The US Health Resources and Services Administration (HRSA) has approved nine drugs for a pilot testing a new rebate model ...

4D Molecular Therapeutics has sold the Asia-Pacific rights to its eye gene therapy to Otsuka Pharmaceutical, securing $85 ...

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

NEW YORK (AP) — The U.S. stock market is pulling back from its record heights on Thursday, as Wall Street sifts through mixed ...

Discover Eli Lilly’s Q3 2025 earnings highlights: record 54% revenue growth, new product approvals, raised guidance, and global expansion.

CEO David Ricks wants Eli Lilly’s upcoming obesity pill to be accessible to patients who need it, but the company still needs ...

Dow Jones Top Company Headlines at 11 AM ET: Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for Metsera | Mounjaro ... Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for ...